A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
Abstract Background Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitoring requirements than regimens containing interferon and ribavirin, and a much higher efficacy in treating hepatitis C (HCV). These characteristics mean that initiating treatment and obtaining a...
Saved in:
Main Authors: | Andrew Radley (Author), Emma Robinson (Author), Esther J. Aspinall (Author), Kathryn Angus (Author), Lex Tan (Author), John F. Dillon (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
by: Sarah R. Donaldson, et al.
Published: (2022) -
P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia
by: B. Hajarizadeh, et al.
Published: (2017) -
Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
by: Nadia A. Nabulsi, et al.
Published: (2020) -
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018) -
High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017)